HMG-CoA reductase (3-hydroxy-3-methyl-glutaryl-coenzyme A reductase, official symbol HMGCR) is the rate-controlling enzyme (NADH-dependent, EC 1.1.1.88;... 34 KB (4,109 words) - 17:09, 10 May 2024 |
β-methylglutaconyl-CoA (MG-CoA) and β-hydroxy β-methylbutyryl-CoA (HMB-CoA). HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid,... 8 KB (959 words) - 23:27, 8 December 2021 |
Statin (redirect from HMG-CoA reductase inhibitor) Statins (or HMG-CoA reductase inhibitors) are a class of medications that reduce illness and mortality in people who are at high risk of cardiovascular... 127 KB (12,736 words) - 18:15, 14 April 2024 |
Mevalonate pathway (redirect from HMG-CoA reductase pathway) The mevalonate pathway, also known as the isoprenoid pathway or HMG-CoA reductase pathway is an essential metabolic pathway present in eukaryotes, archaea... 9 KB (756 words) - 21:39, 21 November 2023 |
Smith–Lemli–Opitz syndrome (redirect from 7-dehydrocholesterol reductase deficiency) 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) to mevalonate, this is an early step in the mevalonate pathway catalyzed by HMG-CoA reductase. Through a complicated... 56 KB (6,555 words) - 00:33, 3 April 2024 |
not tolerated. Statins competitively inhibit hydroxymethylglutaryl (HMG) CoA reductase which is used in the biosynthesis of cholesterol and they include... 30 KB (2,959 words) - 04:45, 3 February 2024 |
Simvastatin (category Drugs developed by Merck & Co.) 3-hydroxy-3-methylglutaryl (HMG) coenzyme A reductase. HMG-CoA reductase, the rate-limiting enzyme of the HMG-CoA reductase pathway, the metabolic pathway... 33 KB (3,247 words) - 00:02, 18 January 2024 |
The discovery of HMG-CoA (3-hydroxy-3-methylglutaryl-CoA) reductase inhibitors, called statins, was a breakthrough in the prevention of hypercholesterolemia... 23 KB (2,423 words) - 18:12, 3 February 2024 |
Lovastatin (category Drugs developed by Merck & Co.) the liver's ability to produce cholesterol by blocking the enzyme HMG-CoA reductase. Lovastatin was patented in 1979 and approved for medical use in 1987... 33 KB (3,305 words) - 20:44, 7 February 2024 |
Hyperlipidemia (section HMG-CoA reductase inhibitors) Common medication therapy is a statin. Competitive inhibitors of HMG-CoA reductase, such as lovastatin, atorvastatin, fluvastatin, pravastatin, simvastatin... 37 KB (3,520 words) - 14:53, 19 February 2024 |
consistent findings on physical examination, the presence of anti HMG-CoA reductase antibodies in a person with myopathy, evidence of muscle breakdown... 12 KB (1,349 words) - 18:07, 19 March 2024 |
medication class of statins. Like other statins, it is an inhibitor of HMG-CoA reductase, the enzyme that catalyses the first step of cholesterol synthesis... 11 KB (995 words) - 09:38, 23 March 2024 |
by a complex 37-step process. This begins with the mevalonate or HMG-CoA reductase pathway, the target of statin drugs, which encompasses the first 18... 79 KB (8,518 words) - 20:19, 27 April 2024 |
C20H32. They are biosynthesized by plants, animals and fungi via the HMG-CoA reductase pathway, with geranylgeranyl pyrophosphate being a primary intermediate... 5 KB (463 words) - 08:11, 6 August 2023 |
Coenzyme Q10 (redirect from Co Q-ten) cholesterol-reducing medications inhibits HMG-CoA reductase. One possible side effect of statins is decreased production of CoQ10, which may be connected to the... 48 KB (4,852 words) - 09:48, 9 May 2024 |
molecular cause of 3-methylcrotonyl-CoA: carboxylase deficiency". Human Molecular Genetics. 10 (12): 1299–306. doi:10.1093/hmg/10.12.1299. PMID 11406611. Huang... 9 KB (1,329 words) - 07:55, 18 August 2023 |